Alnylam Pharmaceuticals, Inc. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of XXX Used as Add-on Therapy in Patients with Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication

MITHRA. A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of XXX for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women.

PFIZER: C3671013 (The Renoir Study): A phase 3 study to evaluate the efficacy, immunogenicity, and safety of respiratory syncytial virus (RSV)perfusion subunit vaccine in adults 2021- ongoing

ASTRA ZENECA – A Phase III Randomized, Double-Blind, Placebo- controlled, Multicenter study to determine the safety and efficacy of AZDxxx for the treatment of COVID-19 in non-hospitalized adults (Tackle) 2021 ongoing.

ASTRA ZENECA – A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZDxxxx, a Combination Product of Two Monoclonal Antibodies (AZDxxxx and AZDxxxx), for Pre-exposure Prophylaxis of COVID-19- PROVENT -2020-ongoing.

ASTRA ZENECA 2020-2021- A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZDxxxx, a Combination Product of Two Monoclonal Antibodies (AZDxxxx and AZDxxxx), for Post -exposure Prophylaxis of COVID-19- STORM CHASER- 2020 ongoing.

SAGENT -A multicenter Randomized Double-blind Placebo controlled of The Efficacy of Camostat Mesylate for the treatment of Confirmed COVID in outpatients N103-CV19-001-2020-2021.

ABBOT – Clinical Evaluation of the Investigational ID NOW™ COVID-19 Assay Protocol 20126012020

Allergan – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH -2019-2020

Bayer– Phase 2b, A randomized, double-blind, parallel-group, multicenter study to assess the efficacy and safety of two different doses of XXXXX versus placebo in women with symptomatic endometriosis- 2019.

AbbVie – A Phase 3b Study to Evaluate the Long-term Safety and Efficacy of XXXXX in Combination with XXXXXX for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women 2018-2019

ObsEva – A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled study investigating the efficacy and safety of daily oral administration of XXXXX alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with Uterine Fibroids in premenopausal women 2019-2020

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of XXX for 12 Weeks in the Treatment of Moderate-to-Severe Atopic Dermatitis

A phase III Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of XXXx in Adult Subjects with psoriatic arthritis

A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of XXX Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea.

An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of XXX for 40 weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea

Prevalence of Negative H Pylori Urease Test in patients with Clinically Diagnosed Peptic Ulcer Disease. 2004

Prevalence of Bowel Disease in Pediatric Patients with Positive Antigliadin (AGA) IgA Antibodies and Antigliadin IgG Antibodies but Negative Tissue Transglutaminase (TTG). 2002 – Children Memorial Hospital Chicago, Illinois.

Clinical trial to evaluate the efficacy and safety of xxxxx vs placebo in treating resistant foot ulcers in subjects with peripheral vascular diseases – Clínica Cardiovascular Colombiana, Medellin Colombia- 1994

Sensitivity and Specific of EKG for Coronary Artery Disease in Climacteric Women.

INVICTUS CLINICAL RESEARCH GROUP LLC
JAN 2020 – CURRENT
Principal Investigator/Primary Care Doctor.

MEDIMORE MD LLC
SEP 2022 – CURRENT
Primary Care Medicine

INVICTUS CLINICAL RESEARCH GROUP LLC–
PREVIOUSLY:
(SCHOOL OF CLINICAL RESEARCH INC 2010 | SCHOOL OF CLINICAL RESEARCH USA, LLC -2015)
APR 2018 – MAR 2020
SUB – Investigator

WATER EDGE DERMATOLOGY VEINISHING
JUL 2018 – SEP 2022
Phlebology

CENTER FOR VEIN RESTORATION
MAY 2017- JUN 2018
Internal Medicine/Primary Care

MILLENNIUM PHYSICIAN GROUP (IMA) INTERNAL MED ASSOCIATES
FEB 2016 – APR 2017
Internal Medicine/Primary Care

PGY3
JUN 2003 – JUN 2005
Internal Medicine Program at Weiss Memorial Hospital
Chicago, IL

PGY 1-PGY2
JUN 2001 – JUN 2003
Internal Medicine Program at Michael Reese Hospital
Chicago, IL

MEDICAL DEGREE
JAN 1989 – DEC 1995
Universidad Pontificia Bolivariana
Medellin, Colombia

BOARD CERTIFIED IN PHLEBOLOGY
FEB 2016
NBPAS

BOARD CERTIFIED IN INTERNAL MEDICINE
APR 2013
ABVLM

BOARD CERTIFIED IN INTERNAL MEDICINE
AUG 2005
ABIM

Women’s Health, Men’s Health, Respiratory Diseases. Vascular Peripheral Diseases, Vein Surgeon, Endocrine- Metabolic Diseases, Cardiovascular Diseases, Rejuvenate Medicine, Nutrition Counseling, Internal Medicine, IBS, NASH, Neurological Diseases, Internal Medicine, Vaccine Studies, Weight Loss.

ICH/GCP Certification, Medidata RAVE ,OSHA, IBM, Signant Health training, InForm , 3152-301-002 eCRF Completion Guidelines Training_V6 – Learning Content, Allergan IWRS Standard Training, Allergan CTMS Site Training Version 2, InForm EDC Fundamentals Introduction, Version 6.0-Learning Content Allergan InForm EDC Fundamentals for Principal Investigators, Version 6.0, ICH E6 (R2) GCP Investigator Site Personnel Training, Version 3.0, Meeting TransCelerate BioPharma Inc. Minimum Criteria Sponsored by Allergan, Safety Reporting in Clinical Trials (using V4 Forms), Allergan Quality Practices, Research Experience.